ArticleClinical and translational allergy2025
Sexual Health in Atopic Dermatitis: Impact of Skin Clinical Control.
Article in Clinical and translational allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sexual Health in Atopic Dermatitis: Impact of Skin Clinical Control.Clinical and translational allergy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSexual health in patients with atopic dermatitis (AD) remains scarcely studied. Identifying the problematic of sexual health disorders (SHD) in AD and associated factors is important for the design and implementation of targeted interventions.
objectiveTo describe the frequency of sexual health disorders (SHD) in AD patients, identify risk factors and assess whether improved AD control with pharmacotherapy is associated with changes in SHD.
methodsWe performed a prospective observational study in AD patients over 18 years of age. Participants completed a survey assessing clinical aspects of SHD and AD at baseline and 5-7 months after initiating specialists-recommended treatment. For AD severity evaluation we used SCORAD and POEM scales and for SHD we used SyDSF-AP, IFSF, and MGH-SFQ.
resultsA total of 221 AD patients were enrolled. At baseline, the frequency of SHD varied according to AD severity (SHD in severe AD 100%, in moderate AD 96%, and in mild AD 56%). Risk factors for SHD were AD severity (SCORAD OR 3.88 [95% CI 2.68-4.73], POEM OR 4.67 [95% CI 3.05-5.79]), skin area affected (OR 3.15 [95% CI 2.88-5.19]), and disease duration (OR 3.75 [95% CI 1.88-4.91]). Improved AD control through pharmacotherapy reduced SHD frequency in mild AD (relative reduction [RR]: -60%), moderate AD (RR: -41%), and severe AD (RR: -28%).
conclusionAtopic dermatitis was frequently associated with SHD even in mild forms of the disease. However, AD clinical control reduced the frequency of SHD, and consequently improving the quality of life of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.